Directors & Senior Leadership
Mr Roger Corbett has been involved in the retail industry for more than 40 years. In 1984, Mr Corbett joined the board of David Jones Australia as a Director of Operations and in 1990 was appointed to the board of Woolworths Limited and to the position of Managing Director of BigW. In 1999, Mr Corbett was appointed Chief Executive Officer of Woolworths Limited, from which he retired in 2006. Mr Corbett is a Director of the Reserve Bank of Australia, a director of Wal-Mart Stores, Chairman of Fairfax Media Limited and Chairman of PrimeAg Australia Limited.
CEO, Managing Director
Mr Richards has more than 25 years’ experience in the pharmaceutical industry and has worked in Europe, the US and Asia. Prior to joining Mayne Pharma, he was President, European Operations and Global Hospital Business of Intas Pharmaceutical Limited where he was responsible for managing their operations in Europe as well as developing the global hospital business with a focus on commercialisation of biosimilar and oncology products. He was also Executive Vice President of the Global Hospital Generics Business at Actavis and spent four years with Mayne Pharma Limited and 14 years with F H Faulding & Co Limited in various roles.
Non Executive Director
The Hon. Ron Best is a highly respected former member of the Victorian Parliament (1988 to 2002), having held a number of senior positions in the National Party of Australia including; Parliamentary Secretary, Shadow Minister for Housing and Spokesman for Health, Housing, Racing, Sport and Recreation. Mr Best has also been a member of various Parliamentary Committees including the Public Accounts and Estimates Committee, the Environmental and Natural Resources Committee and a Board Member of the Victorian Health Promotion Foundation. Prior to his political career Mr Best was the owner of a successful food distribution business and General Manager of the Glacier Food Group. Mr Best was, until 30 June 2013, a Consultant to PFD Food Services Pty Ltd, one of Australia's largest privately-owned food service companies.
Non Executive Director
Mr Bruce Mathieson is currently a Director and was the former Chief Executive Officer of Australian Leisure and Hospitality Group Limited, a joint venture between Woolworths Limited and the Mathieson Family. The ALH Group owns approximately 325 hotels and 520 retail outlets across Australia, and employs more than 15,000 staff. Mr Mathieson has operated in the hotel, leisure and hospitality industry since 1974 and is a well respected member of the Australian business community. He has previously served as a director of the Carlton Football Club. He is trained as an engineer, and brings management and transactional experience from across a number of industries to the Board.
Non Executive Director
Mr Ian Scholes has extensive financial and corporate advisory experience, both in Australia and internationally. Mr Scholes has held senior roles within Merrill Lynch Australia, most recently as Vice Chairman of Investment Banking. Previously Mr Scholes has held the position of Executive General Manager at National Australia Bank, running their corporate and institutional banking division. Mr Scholes is currently a Partner and Chief Executive Officer of Chord Capital Pty Ltd. Mr Scholes has previously held positions on the Board, of St Vincent’s Health as Chairman of the St Vincent’s Foundation and was a former Director of SDI Limited.
Mr Phil Hodges has been involved in the pharmaceutical industry for over 30 years and founded the Metrics Inc. business in 1994. Mr Hodges has overseen the transition of Metrics from a start-up analytical laboratory with four employees to a speciality pharmaceutical company with a portfolio of niche generic products. Prior to starting Metrics, Mr Hodges spent 11 years at Burroughs Wellcome Co. (which became part of GlaxoSmithKline) in the development and validation of analytical methods.
Professor Bruce Robinson
Non Executive Director
Professor Bruce Robinson is highly respected in the medical industry and is Dean of Sydney Medical School at the University of Sydney, a position he has held since 2007. As Dean, he leads one of the largest medical schools in Australia and the most research-intensive faculty within the University of Sydney. Professor Robinson is an Endocrinologist and practices at Sydney’s North Shore Hospital and has been head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989. He has supervised 37 Ph.D. students and has more than 250 research publications. He is also Chairman of Hoc Mai Foundation and RFDS Medical Advisory Committee, a Board Member of the Woolcock Institute, the ANZAC Research Institute, the Centenary Institute for Cancer Research and the Royal Flying Doctor Service (South-Eastern Division).
Group CFO & Company Secretary
Mr Cansdale is a chartered accountant and company secretary with more than 20 years’ experience in the accounting and finance profession. Mr Cansdale was formerly the CFO and Company Secretary at McMillan Shakespeare Limited and prior to that, Vision Systems Limited. Mr Cansdale has extensive experience in the areas of business development, mergers and acquisitions, corporate strategy, tax, financial planning and analysis, risk management, treasury and investor relations. Prior to joining Vision Systems in 2002, Mark held senior finance positions in the insurance and financial services industry at Norwich Union Australia and KPMG.
Chief Scientific Officer
Dr Stancovski has over 20 years of international experience in the pharmaceutical industry and academia. Prior to joining Mayne Pharma, Dr Stancovski was Vice President Research & Development for Actavis Group’s global Hospital Division where she made a significant contribution to expanding the company’s portfolio of complex generic and long-acting injectables, including a number of potential first-to-file projects. Prior to Actavis, Dr Stancovski was the Vice President Scientific Affairs at Intas Pharmaceuticals and also held senior management roles at other multinational pharmaceutical and biotech companies. She holds a Ph.D. in Life Sciences from the Weizmann Institute, Israel and also worked extensively as a post-doctoral scholar at Caltech and MIT in the United States.
Vice President and General Counsel
Ms Rintoul has over 15 years of varied experience in commercial and IP law. Prior to joining Mayne Pharma, Ms Rintoul was special counsel at Minter Ellison Lawyers where she worked closely with Mayne Pharma on various agreements and transactions. Ms Rintoul has also worked for Shell International in The Hague as IP Counsel and for the University of British Columbia’s technology transfer office in Vancouver as a consultant. She has a BSc in Biochemistry, a LLB (Hons) degree and Master of Law (Intellectual Property) from the University of Melbourne.
Executive Vice President, Corporate and Business Development
Mr Paltoglou has over 15 years’ of experience in executing public and private mergers and acquisitions, capital management and providing strategic advice across a range of contexts and market sectors. He was previously Managing Director of Investment Banking at Credit Suisse Emerging Companies in Australia. Prior to Credit Suisse, Mr Paltoglou was a Director of Hindal Group, a boutique M&A advisory business.